During the mid-1990s, new designs of hip resurfacing arthroplasties (HRAs) were introduced. These implants use a metal-on-metal bearing surface with the advantage that there is no polyethylene wear debris. The medium- to long-term results of this new generation of prosthesis seem promising, with few complications ([@CIT0022], [@CIT0004]). Although these metal-on-metal bearings produce less wear debris, the long-term consequences of metal release are unknown. This is especially important since HRA is being used in younger individuals. Studies have shown an increase in plasma levels of chromium and cobalt of about 2--13 times for chromium and 4--7 times for cobalt ([@CIT0023], [@CIT0024]). Furthermore, the formation of pseudotumors as a consequence of metal-on-metal prostheses has been reported ([@CIT0018], [@CIT0025]).

It is claimed that patients can return to their previous activity level and even perform high-impact sports ([@CIT0010], [@CIT0020], [@CIT0006]). We therefore investigated the evidence for this claim. We asked: "What is the therapeutic value of HRA in patients who have undergone HRA for osteoarthritis, measured by quality of life or functional outcomes?"

Methods {#ss2}
=======

In December 2008, we performed a literature search using the PubMed and Embase databases. The search was performed only on the basis of determinant, because of a limited amount of literature on the subject; different synonyms for resurfacing HRA were used (Table 1, see Supplementary data). Search queries were limited to Title/Abstract. Relevant studies were screened for references. Articles in languages other then English, Dutch, French, or German and articles with other domains, determinants, or outcomes were excluded. Further studies were selected according to relevance and were critically appraised according to criteria developed by the Center for Evidence-Based Medicine, Therapy Worksheet, n.d.

Results {#ss3}
=======

The search using the PubMed, Embase and Cochrane databases yielded 245 articles (Figure 1, Supplementary data). Screening on Title/Abstract resulted in 23 articles, and after exclusion of duplicates 15 articles remained. No additional articles were found by cross-referencing. After selection by relevance and critical appraisal, 11 articles remained for inclusion. Articles were considered relevant if they included the domain "patients with osteoarthritis", determinant "HRA" and outcome "clinical outcome" and were aimed at answering our research question. 9 studies were patient series, 1 was a case-control study, and 1 was a randomized controlled trial, which was ranked highest. 3 patient series contained over 500 patients and 2 studies contained more than 200 patients. Median or mean follow-up was less than one year for 2 studies, 1--5 years for 5 studies (which included the randomized controlled trial), and \> 5 years for 4 studies. All patient series showed good clinical outcome scores ([Table 3](#T3){ref-type="table"}). [@CIT0019] found significantly better outcome scores for Birmingham hip replacement (BHR) than for total hip arthroplasty (THA). [@CIT0012] found better outcome scores for HRA than for THA, of which only the differences in global activity scores were statistically significant. [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} and [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} give an overview of the results.

###### 

General study data

  Author       Follow-up                   Mean age             Women (%)                                Men (%)                                  Complication                                      Revision
  ------------ --------------------------- -------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------------- ----------------------------------------------------
  [@CIT0011]   mean 6 (5--8) years         median 51 (16--88)   40                                       60                                       4%                                                29 (4.4%)
  [@CIT0001]   mean 5.6 (1.1--11) years    50 (14--78)          25.3                                     74.4                                     8.1%                                              34 (3.4%)
  [@CIT0008]   mean 71 (60--93) months     54 (35--75)          42                                       58                                       4%                                                4 (3.5%)
  [@CIT0012]   minimum 1 year              48 (23--63)          35/28 **[^b^](#T2-N2){ref-type="fn"}**   65/72 **[^b^](#T2-N2){ref-type="fn"}**   unknown                                           unknown
  [@CIT0021]   mean 4.2 (2.0--7.6) years   52 (17--82)          41                                       59                                       3.8%                                              23 (3.8%)
  [@CIT0026]   median 24 (2--66) months    49 (15--69)          43                                       57                                       3.4%                                              2 (0.8%)
  [@CIT0016]   mean 23.5 (9--40) months    53                   --                                       --                                       unknown                                           unknown
  [@CIT0017]   minimum 6 months            unknown              --                                       --                                       unknown                                           unknown
  [@CIT0019]   mean 61 (52--71) months     50 (18--67)          25/22 **[^b^](#T2-N2){ref-type="fn"}**   75/78 **[^b^](#T2-N2){ref-type="fn"}**   11(21%)/7(11%) **[^b^](#T2-N2){ref-type="fn"}**   1 (1.9%)/4 (6.3%) **[^b^](#T2-N2){ref-type="fn"}**
  [@CIT0002]   median 36 (25--52) months   52 (18--82)          35                                       65                                       10% **[^a^](#T2-N1){ref-type="fn"}** (5.6%)       1 (0.43%)
  [@CIT0014]   mean 8.3 (1--19) months     unknown              --                                       --                                       unknown                                           0

**^a^** superficial wound infections included.

**^b^** THA/HRA

###### 

Results of clinical scores

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author       Preoperative              Follow-up                                                                                                       
  ------------ ------------------------- -------------------- ------------------------------- -------------------- ------------------------------------- --------------------
  [@CIT0011]   47                                                                             95 (84--100) 1-yr\   DAS 6 (5--6)\                         
                                                                                              88 (77--100) 8-yr    95% extremely, satisfied at 7 years   

  [@CIT0001]   3.6 (SD 1.2) pain;\                            9.4 (SD 0.9) pain;\                                                                        
               6.4 (SD 1.4) walking;\                         9.6 (SD 0.9) walking;\                                                                     
               5.8 (SD 1.6) function;\                        9.5 (SD 1.2) function;\                                                                    
               4.7 (SD 1.5) activity                          7.5 (SD 1.6) activity                                                                      

  [@CIT0008]   3.9 (1--10)                                    OHS 41.9 (16--57)               7.5 (4--10)          96.4 (53--100)                        OHS 15.4 (12--49)

  [@CIT0012]                                                  GAS HRA 5.8\                    HRA 7.1\                                                   GAS HRA 17.9\
                                                              GAS THA 5.1                     THA 6.75                                                   GAS THA 12.4\
                                                                                                                                                         WOMAC HRA 8.1\
                                                                                                                                                         WOMAC THA 9.8

  [@CIT0021]                                                                                  6.6 (SD 1.9)                                               OHS 16.1 (SD 7.7)

  [@CIT0026]                             51 (44--60)                                                               96 (85--100)                          

  [@CIT0016]                                                  4.8 (SD 2.3) different sports                                                              4.6 (SD 1.9)\
                                                                                                                                                         sports (NS)\
                                                                                                                                                         85% excellent/good

  [@CIT0017]                             48 (30--67)          65% sports participation                             92 (30--97)                           92% sports\
                                                                                                                                                         participation

  [@CIT0019]                                                                                  THA 7 (3--10)\                                             Sports: THA 33.3%\
                                                                                              HRA 9 (4--10)                                              HRA 73.6%\
                                                                                                                                                         EQ-VAS: THA 69.3\
                                                                                                                                                         HRA 82.3

  [@CIT0002]                             CA 63.9 (8--93);\    SF12 31.1; 58.6\                                     97.7 (60--100)\                       SF12 54.1; 56.9\
                                         CB 56.2 (18--82);\   SF12 30.3; 60.5\                                     99.4 (90--100)\                       SF12 54.1; 57.7\
                                         CC 64.4 (30--98)     SF12 31.5; 52.2                                      85.5 (30--100)                        SF12 48.2; 55.9

  [@CIT0014]                                                  Charnley scores:\                                                                          Pain 5.4\
                                                              Pain 3\                                                                                    Mobility 5.4\
                                                              Mobility 3.1\                                                                              Walking 5.4
                                                              Walking 3.3                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Discussion {#ss4}
==========

In every study, patients and clinicians knew which prosthesis was used; therefore, all studies were subject to certain degrees of bias, most of all confounder bias since validated outcome scores were not used. The study of [@CIT0019] was a case-control study but they restricted patients who received THA in their activities. This also introduces bias. The studies by [@CIT0001] and [@CIT0011] received funding from industry-related companies and institutions. As with any new complex surgical technique, there is a learning curve associated with the surgeon\'s technical ability to perform the procedure. A publication bias may therefore exist, as only surgeons at the top of their learning curve, operating regularly, would obtain sufficient numbers to warrant publication of their cases. Finally, our review suffers from the same publication bias that all literature reviews are subject to: negative findings are less likely to be published.

The studies included quoted variable complication rates ranging from 3% to 10%. This 3-fold difference can be partly explained by the different definitions used by the authors regarding what constituted a complication. Only 4 of the studies had a follow-up period of longer than 5 years. Revision rates were also reported by [@CIT0011] as 4%, by [@CIT0001] as 3%, by [@CIT0008] as 4%, by [@CIT0021] as 4%, by [@CIT0026] as 0.8%, by [@CIT0019] as 2% for THA and 6% for HRA, by [@CIT0002] as 0.4%, and by [@CIT0014] as 0% (Table 4). Although not part of our study aim, these numbers suggest relatively high revision rates with short follow-up. In a study performed by [@CIT0007] on uncemented THA with a minimum follow-up time of 7 years and an endpoint of revision of aseptic loosening of the stem, the survival was between 96% and 100% at 10 years. So complication and revision rates in the studies included are already relatively high. We can only assume that complication rates would be higher with longer follow-up. The literature on THA suggests that augmented revision rates in this type of surgery only start to rise after 7 years.

The use of different clinical outcome scores and the differences in the duration of follow-up make direct comparison between studies difficult. A combination of the University of California Los Angeles activity scale (UCLAS) and Harris hip score (HHS) was used in 5 studies as follow-up scores, but UCLAS was only used in 1 study preoperatively and HHS in 4 ([Table 3](#T3){ref-type="table"}). We found only 2 studies that directly compared HRA with THA. Reviewing the available literature, there is evidence that HRA has a better outcome than THA (as measured by HHS or UCLAS). [@CIT0003] performed a study on 152 patients who underwent THA with an average age of 59 (21--87) years, and an average follow-up of 5 (2--21) years. They found a mean HHS of 89 (SD 14) (range: 40--100) and mean UCLAS score was 6.8 (2--10). Similar outcome scores were found by [@CIT0015] (with a mean HHS of 85 (SD 14) for consultants and of 85 (SD 14) for trainees) and by [@CIT0013] (with a mean HHS of 85 (26--100)).

Conclusion {#ss5}
----------

Our review shows that HRA does have a good clinical outcome with respect to function in the short to medium term, based on data from the 11 available studies. However, the level of this evidence is generally poor with most studies (9) being level 4. [@CIT0019] restricted the activity of the control (THA) group, leading to a distinct possibility of bias. Only 1 study was a randomized controlled trial (Level 1c) involving 209 hips. The functional outcome measures of HHS and UCLAS appear to convey a clinically significant improvement compared to those found in the literature for THA, but there have been very few studies that performed a direct comparison between the two treatment modalities. The clinical outcomes of revision rates and complications are surprisingly high in some of the studies identified here, with relatively short follow-up. Long-term results from these studies are eagerly awaited, to see whether the benefits identified withstand the test of time as robustly as those of THA without a disproportionately high revision rate over a similar follow-up period.
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Supplementary Figure 1 and Table 1 are available at our website ([www.actaorthop.org](www.actaorthop.org)), identification number 3590/10.

###### 

Click here for additional data file.
